| 68.45 0.76 (1.12%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 80.49 | 1-year : | 94.02 |
| Resists | First : | 68.91 | Second : | 80.49 |
| Pivot price | 55.11  |
|||
| Supports | First : | 50.04 | Second : | 38.38 |
| MAs | MA(5) : | 65.31 |
MA(20) : | 53.2 |
| MA(100) : | 43.21 |
MA(250) : | 39.82 |
|
| MACD | MACD : | 5.8 |
Signal : | 4 |
| %K %D | K(14,3) : | 96.5  |
D(3) : | 96.5 |
| RSI | RSI(14): 82.8 |
|||
| 52-week | High : | 68.91 | Low : | 26.55 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ESTA ] has closed below upper band by 5.5%. Bollinger Bands are 221.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 68.9 - 69.1 | 69.1 - 69.33 |
| Low: | 65.74 - 65.98 | 65.98 - 66.26 |
| Close: | 68.01 - 68.39 | 68.39 - 68.81 |
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution. The company sells its products through exclusive distributors and direct sales force in Europe, Latin America, the Asia-Pacific, and internationally. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.
Sat, 08 Nov 2025
US$62.22 - That's What Analysts Think Establishment Labs Holdings Inc. (NASDAQ:ESTA) Is Worth After These Results - Sahm
Sat, 08 Nov 2025
Decoding Establishment Labs Holdings Inc (ESTA): A Strategic SWO - GuruFocus
Fri, 07 Nov 2025
Establishment Labs to Present at Jefferies London Healthcare Conference - Business Wire
Fri, 07 Nov 2025
Is It Time To Consider Buying Establishment Labs Holdings Inc. (NASDAQ:ESTA)? - Yahoo Finance
Fri, 07 Nov 2025
Establishment Labs Holdings (ESTA) Is Up 27.5% After Achieving First Positive Adjusted EBITDA and Raising Guidance - simplywall.st
Thu, 06 Nov 2025
Establishment Labs Holdings Inc. (NASDAQ:ESTA) Q3 2025 Earnings Call Transcript - Insider Monkey
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 29 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 10.7 (%) |
| Held by Institutions | 106.7 (%) |
| Shares Short | 4,780 (K) |
| Shares Short P.Month | 5,100 (K) |
| EPS | -3.08 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.79 |
| Profit Margin | -49.9 % |
| Operating Margin | -27.5 % |
| Return on Assets (ttm) | -12.8 % |
| Return on Equity (ttm) | -261.2 % |
| Qtrly Rev. Growth | 16.2 % |
| Gross Profit (p.s.) | 4.11 |
| Sales Per Share | 6.12 |
| EBITDA (p.s.) | -1.87 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -73 (M) |
| Levered Free Cash Flow | -40 (M) |
| PE Ratio | -22.23 |
| PEG Ratio | 0 |
| Price to Book value | 86.64 |
| Price to Sales | 11.17 |
| Price to Cash Flow | -27.29 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|